Amneal Pharmaceuticals Inc (FRA:2DT)
€ 7.7 0 (0%) Market Cap: 2.45 Bil Enterprise Value: 4.93 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 62/100

Amneal Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 06:55PM GMT
Release Date Price: €2.66 (+1.92%)
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst

Thanks, everybody, for your patience. Sorry I'm a few minutes late. So it is very much my pleasure to welcome the management team of Amneal. And so many of you may not know Chirag Patel because he was behind the scenes running a private company, now running a public company. But obviously, he had created a very significant generic business over several years and was highly effective in building the company. And so he's obviously now in charge of Amneal, and so we're looking to forward to hearing from him. And we also have Todd Branning, who is the company's CFO as well. And so it's great to have you here.

Chirag, maybe you could start with some opening remarks and then we'll go into Q&A.

Chirag K. Patel
Amneal Pharmaceuticals, Inc. - Co-Founder, Co-CEO, President & Director

Well, thank you. It's nice to be back in the saddle. So brother and I both are fully active now as co-CEOs. I mainly focus on the business development,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot